BRPI0617341A2 - processo para o diagnàstico de doenÇas tromboembàlicas e doenÇas coronarianas - Google Patents
processo para o diagnàstico de doenÇas tromboembàlicas e doenÇas coronarianas Download PDFInfo
- Publication number
- BRPI0617341A2 BRPI0617341A2 BRPI0617341-1A BRPI0617341A BRPI0617341A2 BR PI0617341 A2 BRPI0617341 A2 BR PI0617341A2 BR PI0617341 A BRPI0617341 A BR PI0617341A BR PI0617341 A2 BRPI0617341 A2 BR PI0617341A2
- Authority
- BR
- Brazil
- Prior art keywords
- process according
- egln2
- protein
- myocardial infarction
- determined
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 61
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 35
- 208000001435 Thromboembolism Diseases 0.000 title claims abstract description 22
- 238000003745 diagnosis Methods 0.000 title claims abstract description 8
- 101000881650 Homo sapiens Prolyl hydroxylase EGLN2 Proteins 0.000 claims abstract description 52
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 21
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 18
- 102000048660 human EGLN2 Human genes 0.000 claims abstract description 16
- 239000002773 nucleotide Substances 0.000 claims abstract description 15
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 15
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 13
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 13
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 102100037248 Prolyl hydroxylase EGLN2 Human genes 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 208000010125 myocardial infarction Diseases 0.000 claims description 18
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 14
- 208000006011 Stroke Diseases 0.000 claims description 13
- 238000004458 analytical method Methods 0.000 claims description 13
- 230000002028 premature Effects 0.000 claims description 13
- 238000012163 sequencing technique Methods 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 6
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 210000002889 endothelial cell Anatomy 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 229940104230 thymidine Drugs 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000013611 chromosomal DNA Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 230000004952 protein activity Effects 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 238000000018 DNA microarray Methods 0.000 claims description 2
- 238000000636 Northern blotting Methods 0.000 claims description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 238000002105 Southern blotting Methods 0.000 claims description 2
- 208000024798 heartburn Diseases 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 230000004776 neurological deficiency Effects 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- 238000012502 risk assessment Methods 0.000 claims 2
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 238000001215 fluorescent labelling Methods 0.000 claims 1
- 238000000163 radioactive labelling Methods 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000007614 genetic variation Effects 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 102100037249 Egl nine homolog 1 Human genes 0.000 description 3
- 101000881678 Homo sapiens Prolyl hydroxylase EGLN3 Proteins 0.000 description 3
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 3
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 3
- 102100037247 Prolyl hydroxylase EGLN3 Human genes 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000009424 thromboembolic effect Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000881648 Homo sapiens Egl nine homolog 1 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101710170760 Prolyl hydroxylase EGLN2 Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000020874 response to hypoxia Effects 0.000 description 2
- 102200148363 rs672601362 Human genes 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101710111663 Egl nine homolog 1 Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 244000078856 Prunus padus Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005048899.4 | 2005-10-12 | ||
| DE102005048899A DE102005048899A1 (de) | 2005-10-12 | 2005-10-12 | Verfahren zur Diagnose thromboembolischer Erkrankungen und koronarer Herzerkrankungen |
| PCT/EP2006/009517 WO2007042165A1 (de) | 2005-10-12 | 2006-09-30 | Verfahren zur diagnose thromboembolischer erkrankungen und koronarer herzerkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0617341A2 true BRPI0617341A2 (pt) | 2011-07-26 |
Family
ID=37684083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0617341-1A BRPI0617341A2 (pt) | 2005-10-12 | 2006-09-30 | processo para o diagnàstico de doenÇas tromboembàlicas e doenÇas coronarianas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090197774A1 (enExample) |
| EP (1) | EP1937839B1 (enExample) |
| JP (1) | JP2009511026A (enExample) |
| KR (1) | KR20080052662A (enExample) |
| CN (1) | CN101287846A (enExample) |
| AR (1) | AR056125A1 (enExample) |
| AT (1) | ATE525481T1 (enExample) |
| AU (1) | AU2006301578B9 (enExample) |
| BR (1) | BRPI0617341A2 (enExample) |
| CA (1) | CA2625698A1 (enExample) |
| DE (1) | DE102005048899A1 (enExample) |
| IL (1) | IL190585A (enExample) |
| TW (1) | TW200734638A (enExample) |
| WO (1) | WO2007042165A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005048898A1 (de) * | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen |
| EP2311981B1 (en) | 2007-05-01 | 2014-09-17 | The Regents of The University of California | Methods for diagnosing ischemia |
| US20120015904A1 (en) * | 2010-07-14 | 2012-01-19 | Regents Of The University Of California | Biomarkers for diagnosis of transient ischemic attacks |
| CA2804802C (en) | 2010-07-15 | 2023-03-07 | The Regents Of The University Of California | Biomarkers for diagnosis of stroke and its causes |
| US20120316076A1 (en) | 2011-03-04 | 2012-12-13 | The Regents Of The University Of California | Biomarkers for the diagnosis of lacunar stroke |
| CA2856461C (en) * | 2011-12-01 | 2020-08-18 | F. Hoffmann-La Roche Ag | Nt-proanp and nt-probnp for the diagnosis of stroke |
| WO2013103781A1 (en) | 2012-01-07 | 2013-07-11 | The Regents Of The University Of California | Biomarkers for diagnosing ischemia |
| KR101939778B1 (ko) | 2012-07-27 | 2019-01-18 | 삼성전자주식회사 | 필요 혈류량 결정 방법 및 장치, 혈류 영상 생성 방법 및 장치, 심근 관류 영상 처리 방법 및 장치 |
| CN119846215B (zh) * | 2025-01-22 | 2025-07-11 | 广西医科大学附属肿瘤医院 | Egln1乳酸化作为靶点在制备肿瘤诊断试剂盒或治疗药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2474630B1 (en) * | 2002-12-20 | 2016-04-27 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| CA2510895A1 (en) * | 2002-12-20 | 2004-07-15 | Applera Corporation | Genetic polymorphisms associated with stenosis, methods of detection and uses thereof |
-
2005
- 2005-10-12 DE DE102005048899A patent/DE102005048899A1/de not_active Withdrawn
-
2006
- 2006-09-30 US US12/089,624 patent/US20090197774A1/en not_active Abandoned
- 2006-09-30 JP JP2008534895A patent/JP2009511026A/ja not_active Abandoned
- 2006-09-30 WO PCT/EP2006/009517 patent/WO2007042165A1/de not_active Ceased
- 2006-09-30 BR BRPI0617341-1A patent/BRPI0617341A2/pt not_active Application Discontinuation
- 2006-09-30 CA CA002625698A patent/CA2625698A1/en not_active Withdrawn
- 2006-09-30 EP EP06792341A patent/EP1937839B1/de not_active Not-in-force
- 2006-09-30 AT AT06792341T patent/ATE525481T1/de active
- 2006-09-30 KR KR1020087008790A patent/KR20080052662A/ko not_active Withdrawn
- 2006-09-30 AU AU2006301578A patent/AU2006301578B9/en not_active Withdrawn - After Issue
- 2006-09-30 CN CNA2006800376009A patent/CN101287846A/zh active Pending
- 2006-10-05 TW TW095136992A patent/TW200734638A/zh unknown
- 2006-10-10 AR ARP060104446A patent/AR056125A1/es unknown
-
2008
- 2008-04-02 IL IL190585A patent/IL190585A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101287846A (zh) | 2008-10-15 |
| TW200734638A (en) | 2007-09-16 |
| AR056125A1 (es) | 2007-09-19 |
| IL190585A0 (en) | 2008-11-03 |
| AU2006301578B2 (en) | 2011-12-01 |
| ATE525481T1 (de) | 2011-10-15 |
| WO2007042165A1 (de) | 2007-04-19 |
| US20090197774A1 (en) | 2009-08-06 |
| AU2006301578B9 (en) | 2011-12-22 |
| AU2006301578A1 (en) | 2007-04-19 |
| EP1937839A1 (de) | 2008-07-02 |
| CA2625698A1 (en) | 2007-04-19 |
| JP2009511026A (ja) | 2009-03-19 |
| EP1937839B1 (de) | 2011-09-21 |
| DE102005048899A1 (de) | 2007-04-19 |
| IL190585A (en) | 2011-12-29 |
| KR20080052662A (ko) | 2008-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4516990B2 (ja) | ワルファリンの投与量の範囲を予想する方法 | |
| IL190585A (en) | Method for the diagnosis of thromboembolic and coronary heart diseases | |
| BR112016022582B1 (pt) | Marcadores mitocondriais de doenças neurodegenerativas | |
| JP5427352B2 (ja) | ヒト体脂肪量と関連する遺伝子多型に基づく肥満発症リスクの判定方法 | |
| US20020045171A1 (en) | Method of profiling genes as risk factors for attention deficit hyperactivity disorder | |
| JP2013520201A (ja) | 肥満症のマーカーとその使用の方法 | |
| RU2469096C2 (ru) | Способ определения наследственной предрасположенности к развитию инфаркта миокарда у лиц без клинических проявлений ишемической болезни сердца | |
| CN102443630B (zh) | 人ppp2r3a基因突变及其用途 | |
| BRPI0806599A2 (pt) | Marcador e plataforma de diagnóstico para elaboração de fármaco em infarto do miocárdio e falência cardíaca | |
| JP4845486B2 (ja) | 糖尿病性腎症感受性遺伝子、および糖尿病性腎症の予防または治療剤の有効成分のスクリーニング方法 | |
| JP4444576B2 (ja) | ２型糖尿病関連遺伝子 | |
| JP5422805B2 (ja) | 新規糖尿病性腎症感受性遺伝子 | |
| JP4998874B2 (ja) | 炎症性疾患の判定方法 | |
| JP2001252086A (ja) | 方 法 | |
| US20140051074A1 (en) | Method of judging inflammatory disease by using single nucleotide polymorphism | |
| JP5002746B2 (ja) | 抗うつ薬に対する反応性予測に有用な遺伝子多型 | |
| JP4111482B2 (ja) | 循環器疾患の遺伝的要因を判定するための方法及びこれに使用されるオリゴヌクレオチド | |
| US7514211B2 (en) | Genomic DNAs participating in rheumatoid arthritis, method of diagnosing the same, method of judging onset risk and diagnostic kit for detecting the same | |
| JP5235448B2 (ja) | 糖尿病性腎症感受性遺伝子、および糖尿病性腎症の予防または治療剤の有効成分のスクリーニング方法 | |
| JP3684921B2 (ja) | 骨粗鬆症薬剤感受性予測方法 | |
| HK1125414A (en) | Method for diagnosing thromboembolic disorders and coronary heart diseases | |
| JPWO2003083108A1 (ja) | 緑内障発症リスク判断のための遺伝子検査方法 | |
| JPWO2006068111A1 (ja) | ＰＰＡＲγ遺伝子の遺伝子多型に関連する表現型の判定方法 | |
| JP2000175689A (ja) | ヒトミトコンドリアｄｎａ異常の検出方法 | |
| JP2004113093A (ja) | 冠動脈攣縮のリスク診断方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B10A | Cessation: cessation confirmed |
Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, SOLICITADA ATRAVES DA PETICAO NO 020120004019/RJ DE 16/01/2012. |